Murphy Named As OGD Director At US FDA
As CDER’s Corrigan-Curay Assumes Oversight Of FDA Generics Office
The FDA has announced that agency veteran Iilun Murphy will take over leadership of its Office of Generic Drugs. At the same time, CDER principal deputy center director and chair of the GDUFA steering committee Jacqueline Corrigan-Curay will assume oversight of OGD and the FDA’s generics program.
You may also be interested in...
Following its inaugural year, the FDA’s Generic Drug Cluster has formed data sharing arrangements concerning a number of vital indications.
To improve common standards for global development for generics and access to generics, FDA has launched the Generic Drug Cluster through the Global Generic Drug Affairs team established by the FDA’s Office of Generic Drugs. The agency has listed objectives through which it aims to increase scientific alignment among leading generic drug regulatory agencies.
As it announced the formal European Commission approval of its partnered Polpharma Biologics-developed Tyruko natalizumab biosimilar to Tysabri, Sandoz offered Generics Bulletin a timeframe for its expected launch in Europe.